News from NYU Langone Health
Long Island Business News
Eleven Long Island hospitals, including NYU Langone Hospital—Long Island, received an 'A' grade for patient safety in The Leapfrog Group's fall 2025 Hospital Safety Grade report. The report evaluates hospitals on their ability to protect patients from medical errors, accidents, and infections. Joseph J. Greco, MD, executive vice president and chief of hospital operations at NYU Langone Hospital—Long Island, stated that quality and safety are the hospital's top priorities. Other health systems receiving 'A' grades for their hospitals included Northwell Health and Catholic Health.
Also reporting was: ,
11/13/2025
Brooklyn Daily Eagle
NYU Langone hospitals have received their 11th consecutive “A” grade for patient safety and quality from The Leapfrog Group, placing the system in the top 1% of hospitals nationwide for this achievement. The top rating applies to NYU Langone Hospital—Brooklyn, Tisch Hospital, Kimmel Pavilion, and NYU Langone Hospital—Long Island. The Leapfrog Group evaluates nearly 3,000 hospitals on 30 patient safety measures. NewYork-Presbyterian Brooklyn Methodist Hospital also received an A rating, with only 23% of New York hospitals achieving this grade in the fall 2025 survey.
11/13/2025
CNN
Two new studies from doctors at NYU Langone Health show significant progress toward making pig kidney transplants a viable option. Researchers, including Robert Montgomery, MD, DPhil, chair of the Department of Surgery, and director of the NYU Langone Transplant Institute, and Brendan Keating, PhD, associate professor in the Department of Surgery at NYU Grossman School of Medicine, transplanted a genetically modified pig kidney into a brain-dead patient. The organ functioned for 61 days, and the team successfully treated rejection episodes with available medication. This allowed them to map the immune response, bringing them 'measurably closer' to safe pig-to-human organ transplants.
Also reporting was: , , , , ,
11/13/2025
Associated Press
A groundbreaking new therapy being studied at NYU Langone Health by Amit Saxena, MD, associate professor in the Department of Rheumatology and Director, Rheumatology Clinical Research Program, is offering hope to patients with severe autoimmune diseases. The treatment, adapted from cancer's CAR-T therapy, aims to reprogram the body's immune system rather than just suppress it. The article highlights the story of Mileydy Gonzalez, a 35-year-old lupus patient whose disease was attacking her lungs and kidneys, leaving her unable to walk or care for her son. After exhausting other options, her doctor at NYU Langone suggested she enroll in the hospital's CAR-T study. Following the treatment, Gonzalez has made a remarkable recovery and is now pain- and pill-free. "I had forgotten what it was to be me," she said, illustrating the life-changing potential of the research being conducted at NYU Langone.
11/13/2025
WNYW-TV (New York, NY)
Rabia A. De Latour, MD, assistant professor, Department of Medicine, Division of Gastroenterology and Hepatology, discussed new research into the rising rates of colorectal cancer in young adults. She explained that a study has found a potential link between a toxin-producing strain of E. coli and the disease. Del Toro detailed the findings, noting that early-onset cancers were over three times more likely to have a unique DNA signature from this toxin, hypothesizing that an infection early in life could be a contributing factor. She concluded by emphasizing that more research is needed to determine causation and potential prevention strategies.
11/13/2025
CURE Magazine
Joshua Sabari, MD, an assistant professor in the Department of Medicine at NYU Grossman School of Medicine and director of High Reliability Organization Initiatives at NYU Langone's Perlmutter Cancer Center, interviewed Michael Cecchini, MD, of Yale Cancer Center about advances in colorectal cancer from the 2025 European Society for Medical Oncology Congress. Cecchini discussed standard treatments and new third-line data for the antibody-drug conjugate telisotuzumab adizutecan, which showed improved survival. He also noted that data from the DYNAMIC study showed ctDNA-guided therapy for stage 3 colorectal cancer did not improve outcomes and remains investigational.
11/13/2025
SELF Magazine
New research analyzing 154 studies found that venting anger does not help people calm down and may increase angry feelings. The study suggests calming techniques like mindfulness and breathing exercises are more effective. Brad J. Bushman, PhD, study co-author, explains that venting increases arousal levels. Thea Gallagher, PsyD, Director, Wellness Programs, clinical associate professor, Department of Psychiatry, adds that people can productively express frustration by first calming down to understand their feelings and then working toward a solution or acceptance, rather than just ranting.
11/13/2025
Medscape
More than half of people who stop using GLP-1 drugs regain at least some weight within a year, according to new real-world data. The study's author, Michael A. Weintraub, MD, an endocrinologist at NYU Langone Health, clinical assistant professor, Department of Medicine, presented the findings at Obesity Week 2025. He noted the data corroborates clinical trial findings that treatment discontinuation leads to weight recurrence. The study found that at one year post-discontinuation, patients had regained an average of 7.5% of their total body weight. However, 42% of patients were able to maintain their weight loss after stopping the medication.
Also reporting was:
11/13/2025
Trading View
A study from India found that blood-thinning drugs are not equally effective for patients with diabetes following procedures to reopen heart arteries. The trial showed that prasugrel, sold by Eli Lilly, was more effective than AstraZeneca's ticagrelor. The combined rate of heart attack, stroke, bleeding, or death was 14.2% in the prasugrel group compared to 16.6% in the ticagrelor group. Study leader Sripal Bangalore, MD, MHA, FAHA, professor of medicine at NYU Grossman School of Medicine and director of Cardiac Catheterization Laboratory, said the data suggests the two drugs are not interchangeable for this patient population.
Also reporting was: ,
11/13/2025
Los Angeles Times
Autoimmune diseases, which occur when the body's immune system attacks its own tissues, are on the rise and affect tens of millions of people, mostly women. The article explains the difficulty in diagnosing the more than 100 types of these diseases, potential triggers, and treatment complexities. New research is exploring ways to reprogram the immune system, with some early successes. Amit Saxena, MD, rheumatologist and director of NYU Langone’s Rheumatology Clinical Research Program, notes that this is 'probably the most exciting time that we've ever had to be in autoimmunity.'
11/13/2025
TCTMD
The TUXEDO-2 trial found that ticagrelor was not noninferior to prasugrel as part of dual antiplatelet therapy following PCI in patients with diabetes and multivessel coronary disease. The primary composite outcome of death, MI, stroke, or major bleeding occurred more frequently in patients treated with ticagrelor. Reporting at the American Heart Association 2025 Scientific Sessions, study chair Sripal Bangalore, MD, MHA, FAHA, professor of medicine at NYU Grossman School of Medicine and director of Cardiac Catheterization Laboratory, concluded that these findings, combined with previous trial results, support the use of prasugrel over ticagrelor in this patient population.
11/13/2025
Experience Life
This article explains the differences between colds, the flu, and seasonal allergies. Purvi Parikh, MD, clinical assistant professor in the Department of Medicine at NYU Grossman School of Medicine, notes that while all three can cause congestion and fatigue, allergies are not contagious and are distinguished by itchy eyes, nose, or throat. Viruses typically present with full-body symptoms like aches, fever, and chills, and run their course in about seven to 10 days. Parikh adds that seasonal allergies can make individuals more susceptible to viral illnesses due to chronic inflammation and a stressed immune system.
11/13/2025
HealthCentral
Cold weather can worsen multiple sclerosis (MS) symptoms, a phenomenon less known than heat sensitivity. According to Vito P. Arena, MD, clinical assistant professor, Department of Neurology at NYU Grossman School of Medicine, patients often report that their spasticity worsens in the cold, along with locking up, decreased mobility, joint pain, and numbness. The article provides several expert hacks for managing these symptoms during winter months, including dressing in layers, using heating products, consuming warm food and beverages, and staying active indoors to combat seasonal effects on mood and fatigue.
11/13/2025
BK Reader
Brownsville residents are calling for more local breast cancer screening and treatment options, citing a lack of radiology clinics in the area. The article notes that residents must travel to other communities for essential services like mammograms. A report from NYU Langone Health is mentioned, which found that breast cancer rates in Brooklyn rose by 8% between the periods of 2011-2015 and 2016-2020. The American Cancer Society Cancer Action Network also reported that Brownsville has the city's lowest rate of early-stage breast cancer diagnosis, highlighting the need for better resources.
11/13/2025
Aunt Minnie
A research team led by Laura Heacock, MD, associate professor in the Department of Radiology at NYU Langone Health, found that adding MRI data to a multimodal AI algorithm improves breast cancer diagnosis and long-term risk assessment. The model combines information from mammography, tomosynthesis, ultrasound, and MRI with clinical variables. The study, which tested a cohort of 1,944 women, found that including MRI data improved the model's performance for cancer detection and five-year risk prediction. The researchers suggest this approach allows for better targeting of supplemental screening and chemoprevention for high-risk women.
11/13/2025
U.S. Medicine
A new study by researchers from NYU Grossman School of Medicine and the VA New York Harbor Healthcare System found that the initially higher COVID-19 mortality risk for veterans with diabetes had largely disappeared by mid-2022. The retrospective study analyzed a cohort of 426,170 U.S. veterans with COVID-19 between March 2020 and August 2023. Published in PLoS One, the findings show that while diabetes was associated with a higher overall risk of death, these risks attenuated over time, converging with those for veterans without diabetes.
11/14/2025
Medscape
Research presented at the American College of Rheumatology 2025 Annual Meeting suggests somatic mutations in IDH1 and IDH2 genes are linked with inflammation, regardless of whether patients have a hematologic malignancy. Flore Castellan, PhD, a postdoctoral fellow at NYU Grossman School of Medicine, explained that these mutations may drive a treatable premalignant inflammatory condition. The findings indicate that screening for these mutations in patients with undiagnosed systemic inflammatory disorders could lead to targeted treatment with IDH inhibitors, which showed promise in improving symptoms and reducing inflammatory markers in a phase 2 trial.
11/14/2025
